GX方案联合曲妥珠单抗治疗HER-2阳性乳腺癌的临床研究  

The research of trastuzumab in combination with GX chemotherapy in the treatment of metastatic breast cancer with Her-2 positive

作　　者：吴非常[1] 吴祥成[1] 李涛[1] 莫奉山[1] 李宗泰[1] 

机构地区：[1]广东省高州市人民医院,广东高州525200

出　　处：《吉林医学》2014年第4期718-720,共3页Jilin Medical Journal

摘　　要：目的:探讨GX方案联合曲妥珠单抗在HER-2阳性乳腺癌治疗中的价值。方法:将76例her-2阳性乳腺癌患者按家属及患者充分知情自愿原则分为对照组(n=41)与观察组(n=35),对照组患者采用吉西他滨联合卡培他滨方案(GX方案),观察组患者采用曲妥珠单抗联合吉西他滨加卡培他滨方案,观察两组患者第3周的不良反应,第6周的临床疗效及长期随访的无病生存率及生存率。结果:观察组患者的第3周不良反应高于对照,但相比较差异无统计学意义(P>0.05);观察组患者第6周疗效显著高于对照组χ2=18.486,P=0.001,观察组与对照组患者随访3.5年无病生存率分别为24.4%与17.1%(P=0.440),生存率为95.1%与85.7%(P=0.157)。结论:GX方案联合曲妥珠单抗在HER-2阳性乳腺癌患者治疗中具有更高的有效率,可有效提升患者的无病生存率及生存率,且不良反应在可接受范围之内。Objective To explore the value of trastuzumab in combination with GX chemotherapy in the treatment of metastatic breast cancer with Her- 2 positive. Method 76 metastatic breast cancer patients with Her- 2 positive were divided into the control group （n = 41 ） and the observation group （ n = 35 ）. After patients and their families were well informed and voluntary, the control group were treated with gemeitabine plus eapeeitabine （GX chemotherapy） ,the observation group were treated with trastuzumab in eomhination with gemeit- abine, eapeeitabine, the side effects in the third week, the elinieal efl]cacy in the sixth week and the disease -free survival, survival of long - term follow - up were observed. Results The side effects in the 3rd week in the observation group were higher than the control group,but the difference was not statistically significant（ P 〉 0. 05 ）, efficacy in the 6th week in observation group was significantly higher than the con- trol group,x2 = 18. 486 ,P = 0. 001, the disease- free survival rates were （24. 4% vs 17. 1%, P = 0. 440） and the survival rates were （95.1% vs85.7%, P = 0.157） after 3.5a followed - up in the Observation group and control group, respeetivel- ly. Condusion Trastuzumab in combination with GX chemotherapy in the treatment of metastatic breast cancer with Her - 2 positive has a higher eflleieney,it can improve disease- free survival and survival effective, and the toxicity is in the acceptable range.

关 键 词：GX方案 曲妥珠单抗 HER-2阳性 乳腺癌 不良反应 疗效 生存率 

分 类 号：R737.9[医药卫生—肿瘤]